Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natoli

Showing results (1101-1110 of 1,181) with videos related to

Pageof 119
Sort By:
BMJ Open|May 4, 2026
Randomised controlled trial comparing antibiotic cement bead pouch versus negative pressure wound therapy for the management of severe open tibia fracture wounds: Beads versus VAC (BvV) protocolLucas S Marchand, Gerard Slobogean, Nathan N O'Hara, et al.
Science (New York, N.Y.)|September 16, 2021
Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesisEdoardo Del Poggetto, I-Lin Ho, Chiara Balestrieri, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Cell Systems|April 16, 2018
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug PerturbationsLev Litichevskiy, Ryan Peckner, Jennifer G Abelin, et al.
Advances in Therapy|November 23, 2016
Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS)Sebastiano Mercadante, Paolo Marchetti, Arturo Cuomo, et al.
JCO Precision Oncology|December 7, 2020
Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS StudyFrancesco Pantano, Paolo Manca, Grazia Armento, et al.
Cancers|June 6, 2018
Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer PatientsSebastiano Mercadante, Paolo Marchetti, Arturo Cuomo, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Oncotarget|September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experiencePatrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
Pageof 119

Showing results (1101-1110 of 1,181) with videos related to

Sort By:
Pageof 119
BMJ Open|May 4, 2026
Randomised controlled trial comparing antibiotic cement bead pouch versus negative pressure wound therapy for the management of severe open tibia fracture wounds: Beads versus VAC (BvV) protocolLucas S Marchand, Gerard Slobogean, Nathan N O'Hara, et al.
Science (New York, N.Y.)|September 16, 2021
Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesisEdoardo Del Poggetto, I-Lin Ho, Chiara Balestrieri, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Cell Systems|April 16, 2018
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug PerturbationsLev Litichevskiy, Ryan Peckner, Jennifer G Abelin, et al.
Advances in Therapy|November 23, 2016
Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS)Sebastiano Mercadante, Paolo Marchetti, Arturo Cuomo, et al.
JCO Precision Oncology|December 7, 2020
Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS StudyFrancesco Pantano, Paolo Manca, Grazia Armento, et al.
Cancers|June 6, 2018
Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer PatientsSebastiano Mercadante, Paolo Marchetti, Arturo Cuomo, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Oncotarget|September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experiencePatrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
Pageof 119